Document is current

Article History

Received: 2 June 2022

Accepted: 1 February 2023

First Online: 7 February 2023

Declarations

:

: Animal treatments were carried out according to Hungarian Act of Animal Care and Experimentation (1998, XXVIII, Sect. 243), European Communities Council Directive 24 November 1986 (86/609/EEC) and EU Directive 2010/63/EU to use and treat animals in experimental laboratories. All experimental protocols were approved by the Animal Care and Experimentation Committee of the Eötvös Loránd University (Savaria University Centre) and National Scientific Ethical Committee on Animal Experimentation (Hungary) under license number VA/ÉBÁF-ÁO/00279–4/2021. All methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines () for the reporting of animal experiments.

: Not applicable.

: International Patent # PCT/US2014/031237, University of South Florida, D.P.D’Agostino, S. Kesl, Patrick Arnold, “Compositions and Methods for Producing Elevated and Sustained Ketosis”. Patent: US 10,980,764 B1, C. Ari, D.P.D’Agostino, “Exogenous ketone supplements for reducing anxiety-related behavior”; Ari, C., D’Agostino, D.P. Technology Title: “Exogenous Ketone Supplementation Improved Motor Function in Sprague–Dawley Rats.” USF Ref. No: 16A019; Ari, C., D’Agostino, D.P. Technology Title: “Lowering of Blood Glucose in Exercising and Non-Exercising Rats Following Administration of Exogenous Ketones and Ketone Formulas.”USF Ref. No: 16A049; Ari, C., D’Agostino, D.P. Technology Title: “Neuroregeneration improved by ketone.” USF Ref. No: 16B128 (provisional patent); Patent: US 10,945,975 B2: Ari, C.,D’Agostino, D.P. Dean, J.B. Technology Title: “Delaying latency to seizure by combinations of ketone supplements.” Non provisional patent No. 210112–9018-US02 for AC and DPD. Technology Title: “Methods of Increasing Latency of Anesthetic Induction Using Ketone Supplementation”. US Patent Application No. 17/576,375, patent pending: Z. Kovacs, C. Ari, D.P.D`Agostino: „Ketone supplements evoked effect on absence epilepsy by co-administration of Uridine”, D.P. D’Agostino and C. Ari are co-owners of the company Ketone Technologies LLC, and C. Ari is owner of Fortis World LLC. These interests have been reviewed and managed by the University in accordance with its Institutional and Individual Conflict of Interest policies. All authors declare that there are no additional conflict of interest.